Published 2018
| Version v1
Publication
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Description
Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/935462
- URN
- urn:oai:iris.unige.it:11567/935462
Origin repository
- Origin repository
- UNIGE